Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.

Sophie de Guibert , Arnaud Jaccard (1, 2) , Marc Bernard (3) , Pascale Turlure , Dominique Bordessoule (2, 4, 5) , Thierry Lamy

1 PMRIL - Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations
2 Service d'Hématologie biologique [CHU Limoges]
3 LHC - Laboratoire Hubert Curien
4 Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges]
5 UNILIM - Université de Limoges

We report on a series of 24 patients with newly diagnosed mantle cell lymphoma treated with four to six courses of DHAP-rituximab followed by autologous stem cell transplantation for patients <65 years. Three-year overall survival (OS) and event free survival (EFS) rates were 69% and 65% respectively, for the 24 patients. In intent-to-treat analysis, 3-year OS and EFS were 75% and 76% for the 17 patients < 65 years old. This treatment is quite feasible and compares favourably with other regimens.

Domaines: Immunologie

Sophie de Guibert, Arnaud Jaccard, Marc Bernard, Pascale Turlure, Dominique Bordessoule, et al.. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.. Haematologica, 2006, 91 (3), pp.425-6. ⟨hal-00452943⟩